Protagenic Therapeutics Company Insiders
| PTIXW Stock | USD 0.01 0 11.11% |
Protagenic Therapeutics employs about 1 people. The company is managed by 7 executives with a total tenure of roughly 3 years, averaging almost 0.0 years of service per executive, having 0.14 employees per reported executive. Recap of Protagenic Therapeutics' management performance can provide insight into the venture performance.
Protagenic |
Protagenic Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.9017) % which means that it has lost $0.9017 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.0636) %, meaning that it generated substantial loss on money invested by shareholders. Protagenic Therapeutics' management efficiency ratios could be used to measure how well Protagenic Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.21 in 2024. Return On Capital Employed is likely to climb to -1.17 in 2024. At this time, Protagenic Therapeutics' Total Current Assets are fairly stable compared to the past year. Intangible Assets is likely to climb to about 6.4 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 117.2 K in 2024.Common Stock Shares Outstanding is likely to climb to about 4.6 M in 2024, whereas Net Loss is likely to drop (2.4 M) in 2024.
Protagenic Therapeutics Workforce Comparison
Protagenic Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 455. Protagenic Therapeutics adds roughly 1.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Protagenic Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Protagenic Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Protagenic Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Protagenic Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Musci Raymond over a month ago Acquisition by Musci Raymond of 1758 shares of Protagenic Therapeutics at 2.09 subject to Rule 16b-3 | ||
Musci Raymond over a month ago Acquisition by Musci Raymond of 569 shares of Protagenic Therapeutics at 2.07 subject to Rule 16b-3 | ||
Ekizian Gregory over two months ago Disposition of 75000 shares by Ekizian Gregory of Protagenic Therapeutics at 1.0 subject to Rule 16b-3 | ||
Brilliant Digital Entertainment Inc over three months ago Acquisition by Brilliant Digital Entertainment Inc of 758621 shares of Protagenic Therapeutics at 2.9 subject to Rule 16b-3 | ||
Musci Raymond over six months ago Acquisition by Musci Raymond of tradable shares of Protagenic Therapeutics at 2.0 subject to Rule 16b-3 | ||
Robert Stein over six months ago Acquisition by Robert Stein of 200000 shares of Protagenic Therapeutics at 1.75 subject to Rule 16b-3 | ||
Garo Armen over six months ago Acquisition by Garo Armen of 500000 shares of Protagenic Therapeutics at 1.25 subject to Rule 16b-3 |
Protagenic Therapeutics Notable Stakeholders
A Protagenic Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Protagenic Therapeutics often face trade-offs trying to please all of them. Protagenic Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Protagenic Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| MD CFA | CFO Secretary | Profile | |
| Robert MD | Chief Director | Profile | |
| Robert Stein | Chief Director | Profile | |
| CFA MD | CFO Sec | Profile | |
| Garo Armen | CoFounder Chairman | Profile | |
| David Lovejoy | Scientific Officer | Profile | |
| Andrew Slee | Chief Officer | Profile |
About Protagenic Therapeutics Management Performance
The success or failure of an entity such as Protagenic Therapeutics often depends on how effective the management is. Protagenic Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Protagenic management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Protagenic management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.16) | (1.21) | |
| Return On Capital Employed | (1.23) | (1.17) | |
| Return On Assets | (1.16) | (1.21) | |
| Return On Equity | (1.36) | (1.30) |
Please note, the imprecision that can be found in Protagenic Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Protagenic Therapeutics. Check Protagenic Therapeutics' Beneish M Score to see the likelihood of Protagenic Therapeutics' management manipulating its earnings.
Protagenic Therapeutics Workforce Analysis
Traditionally, organizations such as Protagenic Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Protagenic Therapeutics within its industry.Protagenic Therapeutics Manpower Efficiency
Return on Protagenic Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 5M | |
| Net Loss Per Executive | 714.4K | |
| Working Capital Per Employee | 3.5M | |
| Working Capital Per Executive | 506.4K |
Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.